Rheumatoid Arthritis Market to Grow at 6.2% of CAGR to Hit US$ 1.56 billion by 2034 | Fact.MR

Collaborations between healthcare providers and suppliers are strengthening supply chains for rheumatoid arthritis testing kits, driving market growth, says Fact.MR.

/EIN News/ -- Rockville, MD, July 17, 2024 (GLOBE NEWSWIRE) -- Rising awareness about the diagnostic procedures for rheumatoid arthritis and the importance of receiving timely treatment and diagnosis are driving the adoption of medications for the condition. The global Rheumatoid Arthritis Market is expected to reach US$ 857.5 million in 2024 and is further projected to expand at a CAGR of 6.2% from 2024 to 2034.

An inflammatory chronic condition that affects the joints and produces pain and swelling is called rheumatoid arthritis (RA). The body's immune system attacks tissues, including joints, in rheumatoid arthritis.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10040

One of the main factors propelling the growth of the rheumatoid arthritis treatment market is the rising incidence of rheumatoid arthritis globally. The number of chronic autoimmune disorders is expanding, which means there is a growing demand for efficient treatment solutions.

Market growth is driven by the increasing prevalence of RA globally, technological advancements enhancing testing kit performance, and growing awareness about RA diagnosis. Favorable healthcare reimbursement policies and strategic industry initiatives are further contributing to market expansion. These factors are projected to sustain the upward trajectory of the rheumatoid arthritis market.

Top of FormKey Takeaways from the Market Study

• The global rheumatoid arthritis market is projected to expand at a CAGR of 6.2% through 2034.
• Global sales of rheumatoid arthritis medicines are estimated at US$ 857.5 million in 2024.
• The market is forecasted to reach US$ 1.56 billion by 2034-end.
• The North American market is forecasted to expand at a CAGR of 5.6% through 2034.
• Serology tests are estimated to account for 75.5% market share in 2024.
• East Asia is projected to account for 15% of the global market share by 2034.

“Rheumatoid arthritis prevalence is increasing due to changing eating habits, such as the consumption of processed meals high in sugar and harmful fats. This is leading to the rising importance of early diagnosis for the condition,” says a Fact.MR analyst.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=10040

Increasing Aid from Government Assisting Driving Market Growth

Governments worldwide are investing in the discovery of novel and reasonably priced pharmaceuticals for rheumatoid arthritis surveillance and treatment. This is one of the primary drivers projected to propel the rheumatoid arthritis market throughout the study period. Government agencies are sponsoring research and development programs to reduce the workload associated with treating and monitoring rheumatoid arthritis.

Government support for rheumatoid arthritis diagnosis and surveillance is essential to limiting the disease's spread. During the forecast period, rising expenditures on rheumatoid arthritis surveillance and epidemiological monitoring are forecasted to lead to an increase in demand for testing kits.

Key Market Players

List of the prominent players in the global market are AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc., Pfizer Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb, Celgene Corporation

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the rheumatoid arthritis market for 2018 to 2023 and forecast statistics for 2024 to 2034.

The study divulges essential insights into the market based on test type (serology tests, monitoring rheumatoid arthritis treatment efficiency tests) and end user (hospitals, diagnostic laboratories, ambulatory surgical centers), across six major regions of the world (North America, Latin America, Europe, East Asia, South Asia & Oceania, and MEA).

Rheumatoid Arthritis Industry News

A Biocon Ltd. subsidiary, Biocon Biologics Ltd., announced in July 2023 that HULIO (adalimumab-flip) injectable, a biosimilar of Humira (adalimumab), was now available in the United States for the treatment of rheumatoid arthritis.

Checkout More Related Studies Published by Fact.MR Research:

The Global Renal anemia treatment market size is estimated to grow at a CAGR of 7.5% to reach US$ 14.15 billion by the end of 2034

Global single domain antibody platform market to reach US$ 86 million by the end of 2034, expanding at a CAGR of 10.1% over the next decade

The global polycystic ovary syndrome (PCOS) treatment market is projected to grow at a CAGR of 4.7% to reach US$ 6.84 billion by the end of 2034

Global perineal care market size is forecasted to increase at a CAGR of 4.6% to reach US$ 1.88 billion by the end of 2034

Global revenue from spinal cord trauma treatment market is forecasted to increase at a CAGR of 3.7% to reach US$ 4.22 billion by the end of 2034

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.

Follow Us: LinkedIn | Twitter | Blog

Contact:
                    
                    US Sales Office:
                    11140 Rockville Pike
                    Suite 400
                    Rockville, MD 20852
                    United States
                    Tel: +1 (628) 251-1583
                    Sales Team: sales@factmr.com